Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucleic Acid Ther ; 34(1): 26-34, 2024 02.
Artigo em Inglês | MEDLINE | ID: mdl-38386285

RESUMO

Antisense oligonucleotides (AONs) are promising therapeutic candidates, especially for neurological diseases. Intracerebroventricular (ICV) injection is the predominant route of administration in mouse studies, while in clinical trials, intrathecal (IT) administration is mostly used. There is little knowledge on the differences in distribution of these injection methods within the same species over time. In this study, we compared the distribution of splice-switching AONs targeting exon 15 of amyloid precursor protein pre-mRNA injected via the ICV and IT route in mice. The AON was labeled with radioactive indium-111 and mice were imaged using single-photon emission computed tomography (SPECT) 0, 4, 24, 48, 72, and 96 h after injection. In vivo SPECT imaging showed 111In-AON activity diffused throughout the central nervous system (CNS) in the first hours after injection. The 111In-AON activity in the CNS persisted over the course of 4 days, while signal in the kidneys rapidly decreased. Postmortem counting in different organs and tissues showed very similar distribution of 111In-AON activity throughout the body, while the signal in the different brain regions was higher with ICV injection. Overall, IT and ICV injection have very similar distribution patterns in the mouse, but ICV injection is much more effective in reaching the brain.


Assuntos
Encéfalo , Oligonucleotídeos Antissenso , Animais , Camundongos , Distribuição Tecidual , Encéfalo/diagnóstico por imagem , Éxons , Oligonucleotídeos Antissenso/genética , Oligonucleotídeos Antissenso/farmacologia , Injeções Espinhais
2.
Methods Mol Biol ; 2434: 333-341, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35213029

RESUMO

The use of antisense oligonucleotides (AONs) is a promising therapeutic strategy for central nervous system disorders. However, the delivery of AONs to the central nervous system is challenging because their size does not allow them to diffuse over the blood-brain barrier (BBB) when injected systemically. The BBB can be bypassed by administering directly into the brain. Here we describe a method to perform single and repeated intracerebroventricular injections into the lateral ventricle of the mouse brain.


Assuntos
Doenças do Sistema Nervoso Central , Oligonucleotídeos Antissenso , Animais , Barreira Hematoencefálica , Encéfalo , Sistema Nervoso Central , Injeções Intraventriculares , Camundongos , Oligonucleotídeos Antissenso/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...